Avitar set to expand with $10million funding:
This article was originally published in Clinica
Executive Summary
Oral fluid diagnostics specialist Avitar has signed a $10m standby equity financing deal with Cornell Capital Partners. Avitar's chairman and CEO, Peter Phildius, explained that the financing would provide the working capital to invest in resources to "enhance and expand" its ORALscreen business. ORALscreen is a noninvasive, rapid, onsite oral fluid test for drugs of abuse, targeting a $1.5bn market. Avitar will be able to draw $250,000 tranches at any time, up to a maximum of $1m a month. Avitar is based in Canton, Massachusetts.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.